Eris Lifesciences Q4 Review - New Launches Scale-Up Holds Key: Prabhudas Lilladher

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Prabhudas Lilladher Report.Eris Lifesciences Ltd. reported muted operating profit due to higher promotional expenses from new launches. We believe benefits of operating leverage will play out, as revenue scales up from these launches. Further acquisition of Oaknet Healthcare gives Eris Lifesciences an entry in the derma segment, currently operating at sub optimal profitability. Eris Lifesciences’ turnaround of Strides Shasun Ltd. acquired portfolio provides comfort for similar execution. The company continues to outperform cardio metabolic market (60% of its total revenues) which expects robust growth over next three-four years with wide patent expiration opportunities. Our FY23/24E earnings per share stands cut by 6%/3%, as we factor in Oaknet acquisition and lower margin assumption in base business..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Eris Lifesciences Q4 Review - New Launches Scale-Up Holds Key: Prabhudas Lilladher

Eris Lifesciences Q4 Review - New Launches Scale-Up Holds Key: Prabhudas Lilladher

Choose a plan